First-In-Human Phase I Study of a Dual mTOR Kinase and DNA-PK Inhibitor (CC-115) in Advanced Malignancy

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s208720
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2012English

Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors

Investigational New Drugs
OncologyPharmacology
2015English

Erratum To: First-In-Human Phase I Study of SOR-C13, a TRPV6 Calcium Channel Inhibitor, in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy